Completed PHASE3 INTERVENTIONAL 2-arm NCT00613197

EPANOVA in Crohn's Disease, Study 1 (EPIC-1)

A One Year, Multi-center, Randomised, Double-blind Placebo-controlled Parallel-groups Assessment of the Tolerability, Safety and Efficacy of Epanova Soft Gelatin Capsules 4g/Day for Maintenance of Remission of Crohn's Disease.

Sponsor: Tillotts Pharma AG

Conditions Crohn's Disease

Interventions Epanova

Updated 5 times since 2017 Last updated: Apr 3, 2013 Started: Jan 31, 2003 Primary completion: Aug 31, 2006 Completion: Aug 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Crohn's Disease and is currently completed. Tillotts Pharma AG leads this study, which shows 5 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tillotts Pharma AG

Data source: Tillotts Pharma AG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Leuven, Belgium